[1]Lu J, Sun PD. Structural mechanism of high affinity FcγRI recognition of immunoglobulin G. Immunol Rev. 2015;268(1):192-200. doi:10.1111/imr.12346
[2]Kiyoshi M, Caaveiro JM, Kawai T, et al. Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI. Nat Commun. 2015;6:6866. doi:10.1038/ncomms7866
[3]Hulett MD, Hogarth PM. The second and third extracellular domains of FcgammaRI (CD64) confer the unique high affinity binding of IgG2a. Mol Immunol. 1998;35(14-15):989-996. doi:10.1016/s0161-5890(98)00069-8
[4]Mangalam AK, Yadav R. Utility of CD64 Expression on Neutrophils as a Marker to Differentiate Infectious versus Noninfectious Disease Flares in Autoimmune Disorders. Indian J Rheumatol. 2019;14(1):9-11. doi:10.4103/0973-3698.254192
[5]Cid J, Aguinaco R, Sánchez R, García-Pardo G, Llorente A. Neutrophil CD64 expression as marker of bacterial infection: a systematic review and meta-analysis. J Infect. 2010;60(5):313-319. doi:10.1016/j.jinf.2010.02.013
[6]Kern W, Kohlmann A, Schoch C, Schnittger S, Haferlach T. Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias. Cancer. 2006;107(10):2401-2407. doi:10.1002/cncr.22251
[7]Thepen T, Huhn M, Melmer G, Tur MK, Barth S. Fcgamma receptor 1 (CD64), a target beyond cancer. Curr Pharm Des. 2009;15(23):2712-2718. doi:10.2174/138161209788923967
[8]Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
[9]Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889-899. doi:10.1016/S0140-6736(13)60022-7
[10]Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169-182. doi:10.1016/S0140-6736(18)32470-X
[11]Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168-2179. doi:10.1016/S0140-6736(13)61903-0
[12]Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019;39 Suppl 1:19-31. doi:10.1111/liv.14095
[13]Kaneda MM, Cappello P, Nguyen AV, et al. Macrophage PI3K纬 Drives Pancreatic Ductal Adenocarcinoma Progression.聽Cancer Discov. 2016;6(8):870-885. doi:10.1158/2159-8290.CD-15-1346
[14]Hasita H, Komohara Y, Okabe H, et al. Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma. Cancer Sci. 2010;101(8):1913-1919. doi:10.1111/j.1349-7006.2010.01614.x
[15]Thanee M, Loilome W, Techasen A, et al. Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis. Asian Pac J Cancer Prev. 2015;16(7):3043-3050. doi:10.7314/apjcp.2015.16.7.3043
[16]Shen M, Hu P, Donskov F, Wang G, Liu Q, Du J. Tumor-associated neutrophils as a new prognostic factor in cancer: a systematic review and meta-analysis. PLoS One. 2014;9(6):e98259.doi:10.1371/journal.pone.0098259
[17]Tan DW, Fu Y, Su Q, et al. Prognostic Significance of Neutrophil to Lymphocyte Ratio in Oncologic Outcomes of Cholangiocarcinoma: A Meta-analysis. Sci Rep. 2016;6:33789.doi:10.1038/srep33789
[18]Lee BS, Lee SH, Son JH, et al. Neutrophil-lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy. Cancer Immunol Immunother. 2016;65(2):141-150. doi:10.1007/s00262-015-1780-7
[19]Zhang B, Wu Q, Wang Z, et al. The promising novel biomarkers and candidate small molecule drugs in kidney renal clear cell carcinoma: Evidence from bioinformatics analysis of high-throughput data. Mol Genet Genomic Med. 2019;7(5):e607. doi:10.1002/mgg3.607
[20]Sinha R, Winer AG, Chevinsky M, et al. Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection. Nat Commun. 2017;8:15165. Published 2017 May 10. doi:10.1038/ncomms15165
[21]Zhang S, Zhang E, Long J, et al. Immune infiltration in renal cell carcinoma. Cancer Sci. 2019;110(5):1564-1572. doi:10.1111/cas.13996
[22] Barata PC, Rini BI. Treatment of renal cell carcinoma: Current status and future directions. CA Cancer J Clin. 2017;67(6):507-524. doi:10.3322/caac.21411
[23]Shenenberger DW. Cutaneous malignant melanoma: a primary care perspective. Am Fam Physician. 2012;85(2):161-168.
[24]Olbryt M. Molecular background of skin melanoma development and progression: therapeutic implications. Postepy Dermatol Alergol. 2019;36(2):129-138. doi:10.5114/ada.2019.84590
[25] Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Front Immunol. 2016;7:550.doi:10.3389/fimmu.2016.00550
[26]Olbryt M. Molecular background of skin melanoma development and progression: therapeutic implications. Postepy Dermatol Alergol. 2019;36(2):129-138. doi:10.5114/ada.2019.84590
[27]Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98-W102. doi:10.1093/nar/gkx247
[28]Li T, Fan J, Wang B, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017;77(21):e108-e110. doi:10.1158/0008-5472.CAN-17-0307
[29]Li B, Severson E, Pignon JC, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174.doi:10.1186/s13059-016-1028-7
[30]Siemers NO, Holloway JL, Chang H, et al. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS One. 2017;12(7):e0179726.doi:10.1371/journal.pone.0179726
[31]Danaher P, Warren S, Dennis L, et al. Gene expression markers of Tumor Infiltrating Leukocytes. J Immunother Cancer. 2017;5:18. doi:10.1186/s40425-017-0215-8
[32]Hoffmann JJ. Neutrophil CD64: a diagnostic marker for infection and sepsis. Clin Chem Lab Med. 2009;47(8):903-916. doi:10.1515/CCLM.2009.224
[33]Huang YH, Zhu C, Kondo Y, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015;517(7534):386-390. doi:10.1038/nature13848
[34]Cao Y, Zhou X, Huang X, et al. Correction: Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis. PLoS One. 2016;11(3):e0152830.doi:10.1371/journal.pone.0152830
[35]Wiener Z, Kohalmi B, Pocza P, et al. TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol. 2007;127(4):906-914. doi:10.1038/sj.jid.5700616
[36]Mancardi DA, Albanesi M, Jönsson F, et al. The high-affinity human IgG receptor FcγRI (CD64) promotes IgG-mediated inflammation, anaphylaxis, and antitumor immunotherapy. Blood.2013;121(9):1563-1573. doi:10.1182/blood-2012-07-442541
[37]Yeh CF, Wu CC, Liu SH, Chen KF. Comparison of the accuracy of neutrophil CD64, procalcitonin, and C-reactive protein for sepsis identification: a systematic review and meta-analysis. Ann Intensive Care. 2019;9(1):5. doi:10.1186/s13613-018-0479-2
[38]Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. Crit Rev Clin Lab Sci. 2011;48(4):155-170. doi:10.3109/10408363.2011.599831
[39]Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011;13(3):R55. doi:10.1186/bcr2891
[40]Pardo-Cabello AJ, Manzano-Gamero V. Small cell lung cancer elevates procalcitonin levels in the absence of infection. Lung Cancer. 2019;134:272-273. doi:10.1016/j.lungcan.2019.06.018